Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AbbVie must pay 15...

    AbbVie must pay 15 million dollar in Depakote birth-defect trial: jury

    Written by Ruby Khatun Khatun Published On 2017-06-11T11:57:24+05:30  |  Updated On 11 Jun 2017 11:57 AM IST
    AbbVie must pay 15 million dollar in Depakote birth-defect trial: jury

    A federal jury on Friday awarded $15 million to a 10-year-old boy whose mother blamed his birth defect on AbbVie Inc's bipolar disorder drug Depakote that she took while pregnant, in the latest trial among hundreds of lawsuits over the product.


    Jurors in federal court in East St. Louis, Illinois, awarded the compensatory damages to Stevie Gonzalez, who was born with spina bifida. His mother, Christina Raquel, said she was not adequately warned about a risk of birth defects when she took Depakote while pregnant.


    Jurors awarded no punitive damages during a second phase of the trial, according to court papers. The lawsuit was filed against Abbott Laboratories Inc.


    AbbVie spun out of Abbott in 2013 and assumed all rights and responsibilities for the drug. About 695 injury claims related to Depakote are pending in federal and state courts, according to AbbVie.


    In a statement, AbbVie said in several prior cases, "juries have unanimously found that Depakote’s label enables doctors to make properly informed decisions about Depakote’s demonstrated benefits and the clearly disclosed risk of birth defects."


    Lawyers for the plaintiffs did not immediately respond to requests for comment.


    In 2012, Abboutt agreed to pay $1.6 billion to resolve federal and state claims that it promoted Depakote for uses that were not approved by U.S. health regulators.


    In her lawsuit, Raquel claimed that her child was born in 2007 with birth defects after she took Depakote to treat her bipolar disorder while she was pregnant.


    The lawsuit said Abbott failed to provide adequate warnings to her psychiatrists regarding the risk of birth defects associated with Depakote use.


    Lawyers for the company said doctors were warned about the drug's risks. It also argued Raquel cannot prove Depakote caused her child's injuries.


    Depakote cases have had mixed results in court. In 2015, a Missouri state court jury awarded 24 plaintiffs $38 million.


    But a federal jury in Ohio in 2015 cleared Abbott and AbbVie of liability in another lawsuit. In February, another federal jury in Ohio returned a defense verdict.


    The case is E.R.G., a minor, by Christina Raquel, individually as parent and next friend of E.R.G., v. Abbott Laboratories Inc, U.S. District Court, Southern District of Illinois, No. 15-cv-00702.


    (Reporting by Nate Raymond in Boston; Editing by David Gregorio and Cynthia Osterman)

    AbbottAbbViebipolar disorder drugbirth defectsChristina RaquelDepakotefederal courtlawsuitsspina bifidaStevie Gonzalez
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok